Citadel Advisors’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-245,555
Closed -$4.58M 14840
2022
Q1
$4.58M Buy
245,555
+107,829
+78% +$1.94M ﹤0.01% 4347
2021
Q4
$2.95M Buy
137,726
+43,703
+46% +$861K ﹤0.01% 5374
2021
Q3
$1.74M Sell
94,023
-45,918
-33% -$925K ﹤0.01% 6724
2021
Q2
$3M Sell
139,941
-38,757
-22% -$788K ﹤0.01% 5609
2021
Q1
$3.45M Buy
+178,698
New +$3.15M ﹤0.01% 5105

Other funds holding OCDX

Citadel Advisors's OCDX Position: Q2 2022 in Review

Citadel Advisors sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 245,555 shares — an estimated $4.58M sold.

Citadel Advisors first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $4.58M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

  • Citadel Advisors reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 245,555 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $4.58M.
  • Citadel Advisors first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
  • Citadel Advisors's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $4.58M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.